Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

AZN : 66.17 (+0.08%)
MRK : 107.50 (+0.64%)
ANGN : 0.9000 (+5.88%)
CLVS : 0.3460 (+1.76%)
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication

Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.

GSK : 33.99 (+0.89%)
MRK : 107.50 (+0.64%)
ABBV : 159.62 (+0.14%)
IMGO : 35.66 (+0.06%)
4 Stocks to Buy That Have Caught Wall Street's Attention

With strong indications of slowing interest rate hikes by the Fed poised to feed the stock market rally, it could be wise to invest in Merck (MRK), AT&T (T), Mosaic (MOS), and Photronics (PLAB), which...

MOS : 51.77 (+2.31%)
MRK : 107.50 (+0.64%)
PLAB : 18.69 (-1.58%)
T : 19.12 (+0.16%)
2 Stocks the Smart Money on Wall Street Owns the Majority Right Now

The Federal Reserve is expected to lower the pace of its rate hikes from next month. However, concerns about an economic slowdown are still evident. Hence, this might be the time to follow the smart money...

MRK : 107.50 (+0.64%)
YELP : 29.64 (+0.24%)
Novartis (NVS) Set to Advance Malaria Drug Into Phase III

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

NVS : 87.71 (+0.48%)
BIIB : 305.15 (+0.56%)
RHHBY : 41.0600 (+1.08%)
MRK : 107.50 (+0.64%)
Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision...

BMY : 79.24 (+0.13%)
MRK : 107.50 (+0.64%)
AMGN : 283.74 (+0.12%)
MRTX : 98.62 (+2.89%)
AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

MRK : 107.50 (+0.64%)
GILD : 86.26 (+0.98%)
VRTX : 312.98 (-1.01%)
ABBV : 159.62 (+0.14%)
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

BMY : 79.24 (+0.13%)
MRK : 107.50 (+0.64%)
VRTX : 312.98 (-1.01%)
ANGN : 0.9000 (+5.88%)
GSK to Withdraw Blenrep From U.S. Market on FDA Request

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

GSK : 33.99 (+0.89%)
MRK : 107.50 (+0.64%)
GILD : 86.26 (+0.98%)
VRTX : 312.98 (-1.01%)
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co

Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.

XOM : 113.21 (-0.35%)
MRK : 107.50 (+0.64%)
ADM : 97.40 (+0.64%)
MCK : 383.34 (+0.68%)
MPC : 125.20 (-0.32%)

Barchart Exclusives

Chinese Stocks and the FXI
Chinese stocks traded on the Hong Kong and foreign exchanges have been toxic over the past years. While the US stock market has been ugly in 2022, Chinese stocks and the FXI ETF product have done worse. Value-seeking investors have been buying the FXI since late October, and time will tell if the purchases end in more disappointment. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar